Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466011 | 0.91 | CHRM1 (0.56) | CHRM1ALDH1A1KDM4ETMEM97ACHE | |
| SCHEMBL3467416 | 0.89 | CHRM1 (0.65) | CHRM1ALDH1A1LMNAMAPTKCNJ1 | |
| SCHEMBL3187069 | 0.85 | CHRM1 (0.73) | CHRM1SOS1KCNH2 | |
| SCHEMBL3187077 | 0.85 | CHRM1 (0.73) | CHRM1SOS1KCNH2 | |
| SCHEMBL4795500 | 0.85 | CHRM1 (0.60) | CHRM1ALDH1A1LMNAMAPTKCNJ1 | |
| SCHEMBL3467844 | 0.83 | CHRM1 (0.63) | CHRM1ALDH1A1SMN1; SMN2KDM4EKCNH2 | |
| SCHEMBL508705 | 0.83 | CHRM1 (0.73) | CHRM1SOS1KCNH2 | |
| SCHEMBL3194998 | 0.83 | CHRM1 (0.73) | CHRM1ALDH1A1MAPTSMN1; SMN2SOS1 | |
| SCHEMBL509156 | 0.83 | CHRM1 (0.73) | CHRM1ALDH1A1MAPTSMN1; SMN2SOS1 | |
| SCHEMBL29808816 | 0.83 | CHRM1 (0.73) | CHRM1ALDH1A1LMNAKCNH2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678791-B2 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE IP VENTURES, L.P. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | CUMBRE PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008008480-A2 | NITROHETEROARYL-CONTAINING RIFAMYCIN DERIVATIVES | CUMBRE PHARMACEUTICALS INC. (US) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139577-A1 | Nitroheteroaryl-containing rifamycin derivatives | NRDC, FNTB, RIF1 | CHRM1 4498/4885ALDH1A1 1997/4885LMNA 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.